DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan-Reference-Cited by-同舟云学术

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

Published:2015-06-22 Issue:3 Volume:80 Page:581-588
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Falvella Felicia Stefania¹,Cheli Stefania¹,Martinetti Antonia²,Mazzali Cristina³⁴,Iacovelli Roberto²,Maggi Claudia²,Gariboldi Manuela⁵⁶,Pierotti Marco Alessandro⁷,Di Bartolomeo Maria²,Sottotetti Elisa²,Mennitto Roberta²,Bossi Ilaria²,de Braud Filippo²,Clementi Emilio⁸⁹,Pietrantonio Filippo²

Affiliation:

1. Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences; University Hospital ‘Luigi Sacco’, Università di Milano; Milan Italy

2. Medical Oncology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy

3. Department of Biomedical and Clinical Sciences; University Hospital ‘Luigi Sacco’, Università di Milano; Milan Italy

4. Department of Management; Economics and Industrial Engineering, Politecnico di Milano; Milan Italy

5. Department of Experimental Oncology and Molecular Medicine; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy

6. FIRC Institute of Molecular Oncology Foundation; Milan Italy

7. Scientific Directorate; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy

8. Scientific Institute, IRCCS E. Medea, Bosisio Parini; Lecco Italy

9. Unit of Clinical Pharmacology, Department of Biomedical, Clinical Sciences; Consiglio Nazionale delle Ricerche Institute of Neuroscience, University Hospital ‘Luigi Sacco’, Università di Milano; Milan Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12631/fullpdf

Reference29 articles.

1. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment;Grothey;J Clin Oncol,2004

2. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

3. Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest;Falcone;J Clin Oncol,2007

4. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014

5. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing;Caudle;Clin Pharmacol Ther,2013

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy;International Journal of Molecular Sciences;2024-08-04

2. MIR27A rs895819 TC Genotype Increases Risk of Fluoropyrimidine-Induced Severe Toxicity Independently of DPYD Variations;Pharmacogenomics;2024-01

3. Genetic Variants as Predictors of the Success of Colorectal Cancer Treatments;Cancers;2023-09-22

4. Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis;Value in Health Regional Issues;2023-09

5. Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction;International Journal of Molecular Sciences;2023-08-27